Complete remission of a high risk metastatic rhabdomyosarcoma in an adolescent treated with a liposomal (Myocet®) regimen

Aurélie Phulpin-Weibel, Ludovic Mansuy, Valérie Bernier-Chastagner, Marie-Agnès Galloy, Pierre Bordigoni, Pascal Chastagner

Abstract


We report the case of a very high risk metastatic rhabdomyosarcoma teenager treated with an induction therapy using only liposomal doxorubicin (Myocet®) because of his extremely bad health condition. A near complete remission was obtained after 2 courses. Then he received conventional chemotherapy according to the EpSSG protocol, radiotherapy and a reduced-intensity conditioning regimen followed by pheno-identical allogeneic stem cell transplantation. He is in continuous complete remission with a follow-up of nine years.

Keywords


metastatic rhabdomyosarcoma; liposomal anthracycline

Full Text:

PDF

References


Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21:78-84.

Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26:2384-2389.

Bergeron C, Thiesse P, Rey A, et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 2008; 44:427-431.

Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002; 8:413-418.

Stavridi F, Palmieri C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther 2008; 8:1859-1869.

Bisogno G, Ferrari A, Bergeron C, et al. The IVADo regimen-a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005; 103:1719-1724.

Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343:750-758.

Chan KW, Rogers PC, Fryer CJ. Breast metastases after bone marrow transplantation for rhabdomyosarcoma. Bone Marrow Transplant 1991; 7:171-172.

Misawa A, Hosoi H, Tsuchiya K, et al. Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 2003; 20:151-155.

Doelken R, Weigel S, Schueler F, et al. Poor outcome of two children with relapsed stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2005; 22:699-703.

Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AM, et al. Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant 2009; 43:179-180.

Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/ Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19:227-231.

Ohta H, Hashii Y, Yoshida H, et al. Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2011; 33:e35-38.




DOI: http://dx.doi.org/10.22551/2014.02.0102.10012

Copyright (c)

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975